fashion -WSS

fashion

author：leisure time 2025-09-06 02:11:28 - browse：636

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Merck drug for rare lung condition set for approval in U.S.

WSS

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Let's speed up science by embracing open access publishing

Covid vaccine financial winners and losers, from Pfizer to Novavax

Will generative AI in health care meet the fate of IBM's Dr. Watson?

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Primary care physicians play key roles in Alzheimer's management

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

ASCO: Palliative care found as helpful given virtually as in person

At least 13 dead in Texas as scorching temps continue

ASCO: AstraZeneca says CAR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA's naming rule on biosimilars has undermined competition

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Trump demands the U.S. pay no more for drugs than other countries … again

Washington mulls new rules to avert another Change Healthcare

hotspot

Shifting the focus from loneliness to social health

Merck drug for rare lung condition set for approval in U.S.

Scientists boost immune system in aging mice by making it youthful

Letters to First Opinion on caregivers, digital health, and more

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Wikipedia

hotspot

hotspot

explore